Nuvectis Pharma, Inc. (NVCT) stock
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.11−1.13 (-5.58%)
Close on Nov 16, 2026Market cap $622.63MP/E –Yield 0.00%
Nuvectis Pharma cash
Cash and short-term investments held at the end of each period.
Nuvectis Pharma's cash was $22.16M at Jun 30, 2026. For fiscal 2025 it was $31.63M, up 70.7% from the year before. The highest annual figure on record is $31.63M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.63M | +70.7% |
| FY2024 | Dec 31, 2024 | $18.53M | -3.1% |
| FY2023 | Dec 31, 2023 | $19.13M | -4.3% |
| FY2022 | Dec 31, 2022 | $19.99M | +248.2% |
| FY2021 | Dec 31, 2021 | $5.74M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.16M | -17.3% |
| Q1 FY2026 | Mar 31, 2026 | $25.13M | -15.9% |
| Q4 FY2025 | Dec 31, 2025 | $31.63M | +70.7% |
| Q3 FY2025 | Sep 30, 2025 | $35.44M | +106.4% |
| Q2 FY2025 | Jun 30, 2025 | $26.79M | +47.9% |
| Q1 FY2025 | Mar 31, 2025 | $29.86M | +53.4% |
| Q4 FY2024 | Dec 31, 2024 | $18.53M | -3.1% |
| Q3 FY2024 | Sep 30, 2024 | $17.17M | -22.2% |
| Q2 FY2024 | Jun 30, 2024 | $18.12M | -26.4% |
| Q1 FY2024 | Mar 31, 2024 | $19.46M | +25.8% |
| Q4 FY2023 | Dec 31, 2023 | $19.13M | -4.3% |
| Q3 FY2023 | Sep 30, 2023 | $22.06M | -6.7% |
| Q2 FY2023 | Jun 30, 2023 | $24.60M | +81.3% |
| Q1 FY2023 | Mar 31, 2023 | $15.47M | -7.3% |
| Q4 FY2022 | Dec 31, 2022 | $19.99M | +248.2% |
| Q3 FY2022 | Sep 30, 2022 | $23.64M | +247.2% |
| Q2 FY2022 | Jun 30, 2022 | $13.57M | +88.1% |
| Q1 FY2022 | Mar 31, 2022 | $16.69M | – |
| Q4 FY2021 | Dec 31, 2021 | $5.74M | – |
| Q3 FY2021 | Sep 30, 2021 | $6.81M | – |
| Q2 FY2021 | Jun 30, 2021 | $7.21M | – |
See a number that looks wrong?